Abstract 1724P
Background
In Botswana, 65% of breast cancers present at an advanced stage due to multifactorial delays. The WHO Global Breast Cancer Initiative recommends a maximum of 60 days of lead time in diagnostic workup and strongly advocates for the use of patient Navigation. A Patient Navigation Project was created to improve the timely diagnosis and treatment of breast cancer patients around Gaborone, the capital.
Methods
A 2-day theoretical and practical course was delivered in March 2022 to 15 clinical navigators (nurses from 6 district Hospitals and from the Referral Hospital) and 7 non-clinical navigators (advocacy groups). A navigation coordinator served as the point of contact, reported on program outcomes and provided smartphone airtime. Different virtual communication groups were created with navigators to accelerate patient flow and facilitate problem solving.
Results
Between April 2022 and July 2023, 75 patients were included in the navigation program: 21 were in early stages (stages I and II) (28%) and 53 in advanced stages (stages 3 and 4) (71%). From those patients, 46% received neoadjuvant chemotherapy, 17% adjuvant chemotherapy and 25% palliative therapy. Navigation enabled faster access to CT-scan staging, unveiling more stage IV disease (23%), thus avoiding inappropriate curative treatments.
Table: 1724P
Key navigation challenges and improvements
Key persistent challenges | Key improvements |
Delays in biopsy (needle shortages) | Biopsies and staging done locally, avoiding referral delays for diagnostic workup |
Delays in obtaining biopsy and IHC results (pathology backlogs, loss of sample, reagent shortages) | Fast referral pathway for patients in need of urgent consultation |
Patient transport issues | Closer tracking of patients and tests results |
Treatment delays: Stock-outs of drugs (hormone therapy, chemotherapy) and radiation therapy delays | Facilitated access to counselling and transport services |
Time constraints: Limited time allocated to navigation | Increased multidisciplinary collaboration |
Conclusions
The Botswana Breast Cancer Navigation project succeeded in implementing Cancer Navigation in accordance with international guidelines. It improved management of breast cancer patients through a smoother access to diagnosis and treatment, and it addressed barriers to care for specific situations. Many navigation sites referred patients with upfront biopsy diagnosis and minimal staging, and this reduced the time from first consultation in breast clinic to treatment (median delay 22 days). Dr Migeotte and Dr Soares de Pinho contributed equally to this work.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Botswana-Rutgers Partnership for Health.
Funding
UICC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1912TiP - STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Presenter: Sumanta Pal
Session: Poster session 23
2366P - Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Presenter: Daniel Castellano Gauna
Session: Poster session 23
2367P - A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Russells Pachynski
Session: Poster session 23
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
2369P - Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Presenter: Bradley McGregor
Session: Poster session 23
2370P - Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Achille Bottiglieri
Session: Poster session 23
2371P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Presenter: Shilpa Gupta
Session: Poster session 23
2372P - Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Presenter: Marc-Oliver Grimm
Session: Poster session 23
2373P - Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361
Presenter: Ronac Mamtani
Session: Poster session 23
2374P - A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Presenter: Petros Grivas
Session: Poster session 23